Spotlight on orlistat in the management of patients with obesity

Treatments in Endocrinology

Volumn 4, Issue 2, 2005, Pages 127-129

  Curran, Monique P ^a   Scott, Lesley J ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TETRAHYDROLIPSTATIN;

COMORBIDITY; DIET RESTRICTION; DISEASE ASSOCIATION; DRUG TOLERABILITY; ENZYME INHIBITION; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; LIFESTYLE; LIPID ABSORPTION; LOW CALORY DIET; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; WEIGHT REDUCTION;

ANTI-OBESITY AGENTS; HUMANS; LACTONES; OBESITY;

EID: 17144365398     PISSN: 11756349     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024677-200504020-00006     Document Type: Review

References (46)

1. Hvizdos KM, Markham A. Orlistat: a review of its use in the management of obesity. Drugs 1999 Oct; 58 (4): 743-60
2. Guerciolini R. Mode of action of orlistat. Int J Obes 1997; 21 Suppl. 3: S12-23
3. Zhi J, Melia AT, Guerciolini R, et al. Retrospective population-based analysis of the dose-response (fecal fat excretion) relationship of orlistat in normal and obese volunteers. Clin Pharmacol Ther 1994; 56 (1): 82-5
4. Borovicka J, Schwizer W, Guttmann G, et al. Role of lipase in the regulation of postprandial gastric acid secretion and emptying of fat in humans: a study with orlistat, a highly specific lipase inhibitor. Gut 2000 Jun; 46 (6): 774-81
5. Wauters M, Considine RV, Van Gaal LF. Human leptin: from an adipocyte hormone to an endocrine mediator. Eur J Endocrinol 2000; 143 (3): 293-311
6. Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of Diabetes in Obese Subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004 Jan; 27 (1): 155-61
7. Lucas CP, Boldrin MN, Reaven GM. Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia. Am J Cardiol 2003 Apr 15; 91 (8): 961-4
8. Guy-Grand B, Drouin P, Eschwege E, et al. Effects of orlistat on obesity-related diseases: a six-month randomized trial. Diabetes Obes Metab 2004 Sep; 6 (5): 375-83
9. Erdmann J, Lippl F, Klose G, et al. Cholesterol lowering effect of dietary weight loss and orlistat treatment: efficacy and limitations. Aliment Pharmacol Ther 2004 Jun 1; 19 (11): 1173-9
10. Muls E, Kolanowski J, Scheen A, et al. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes Relat Metab Disord 2001 Nov; 25 (11): 1713-21
11. Broom I, Hughes E, Dodson P, et al. The role of orlistat in the treatment of obese patients with mild to moderate hypercholesterolaemia: consequences for coronary risk. Br J Cardiol 2002; 9 (8): 460-8
12. Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 2002 Nov; 4 (6): 415-23
13. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes: a 1-year randomized double-blind study. Diabetes Care 1998 Aug; 21 (8): 1288-94
14. Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002 Jul; 25 (7): 1123-8
15. Shi Y-F, Pan C-Y, Gao Y. Orlistat improves glycaemic control and weight loss in overweight and obese Chinese patients with newly diagnosed and previously untreated type 2 diabetes [abstract no. 691]. Diabetologia 2004; 47 Suppl. 1: A250
16. Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: a 1-year randomized controlled trial. Diabetes Care 2002 Jun; 25 (6): 1033-41
17. Halpern A, Mancini MC, Suplicy H, et al. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. Diabetes Obes Metab 2003 May; 5 (3): 180-8
18. Bakris G, Calhoun D, Egan B, et al. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens 2002 Nov; 20 (11): 2257-67
19. Bloch KV, Salles GF, Muxfeldt ES, et al. Orlistat in hypertensive overweight/obese patients: results of a randomized clinical trial. J Hypertens 2003 Nov; 21 (11): 2159-65
20. Ozcelik O, Dogan H, Kelestimur H. Effects of a weight-reduction program with orlistat on serum leptin levels in obese women: a 12-week, randomized, placebo-controlled study. Curr Ther Res Clin Exp 2004 Mar; 65 (2): 127-37
21. Rissanen P, Vahtera E, Krusius T, et al. Weight change and blood coagulability and fibrinolysis in healthy obese women. Int J Obes Relat Metab Disord 2001 Feb; 25: 212-8
22. Karhunen L, Franssila-Kallunki A, Rissanen P, et al. Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns. Int J Obes Relat Metab Disord 2000 Dec; 24(12): 1567-72
23. Chanoine J-P, Hauptman J, Boldrin M, et al. Beneficial effects on orlistat on weight and body composition in obese adolescents [abstract no. T7b:P7b-030 plus poster]. Int J Obes 2004; 28 Suppl. 1: S195
24. Trouillot TE, Pace DG, McKinley C, et al. Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss. Am J Gastroenterol 2001 Jun; 96 (6): 1888-94
25. Zhi J, Mulligan TE, Hauptman JB. Long-term systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients. J Clin Pharmacol 1999 Jan; 39(1): 41-6
26. Zhi J, Melia AT, Funk C, et al. Metabolic profiles of minimally absorbed orlistat in obese/overweight volunteers. J Clin Pharmacol 1996; 36 (11): 1006-11
27. Zhi J, Moore R, Kanitra L, et al. Pharmacokinetic evaluation of the possible interaction between selected concomitant medications and orlistat at steady state in healthy subjects. J Clin Pharmacol 2002 Sep; 42 (9): 1011-9
28. Broom I, Wilding J, Stott P, et al. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multi-morbidity Study. Int J Clin Pract 2002 Sep; 56 (7): 494-9
29. Krempf M, Louvet JP, Allanic H, et al. Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity. Int J Obes Relat Metab Disord 2003 May; 27 (5): 591-7
30. Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med 2000 Sep; 248 (3): 245-54
31. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281 (3): 235-42
32. Hauptman J, Lucas C, Boldrin MN, et al. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000 Feb; 9 (2): 160-7
33. Rossner S, Sjostrom L, Noack R, et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity: European Orlistat Obesity Study Group. Obes Res 2000 Jan; 8(1): 49-61
34. Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients: European Multicentre Orlistat Study Group. Lancet 1998 Jul 18; 352 (9123): 167-72
35. Broom I, Lindgarde F, Guy-Grand B, et al. Weight loss at lead-in is not a predictor for weight loss success with orlistat in patients with multimorbidities. Int J Obes 2004; 28 Suppl. 1: S152
36. Rissanen A, Lean M, Rossner S, et al. Predictive value of early weight loss in obesity management with orlistat: an evidence-based assessment of prescribing guidelines. Int J Obes Relat Metab Disord 2003 Jan; 27 (1): 103-9
37. Torgerson JS, Hauptman J, Boldrin M, et al. Efficacy of orlistat plus lifestyle changes in risk reduction of type 2 diabetes in obese patients with metabolic syndrome: a comparative analysis using National Cholesterol Education Program Adult Treatment Panel III vs European group for the study of insulin resistance criteria [abstract no. 690]. Diabetologia 2004; 47 Suppl. 1: A249
38. Caterson I, Guy-Grand B, Hill J. Efficacy of orlistat in overweight and obese patients with metabolic syndrome [abstract plus poster presented at the 12th European Congress on Obesity: 2003 May 29-Jun 1: Helsinki]. Int J Obes Relat Metab Disord 2003 Sep 9; 27: 1139
39. Jacob S, Ziegler O, Toplak H, et al. Orlistat improves all components of the metabolic syndrome in overweight and obese patients on two diets [abstract no. T5P5b-011 plus poster presented at the 13th European Congress on Obesity: 2004 May 26-9: Prague]. Int J Obes 2004; 28 Suppl. 1: S154
40. Lamotte M, Annemans L, Lefever A, et al. A health economic model to assess the long-term effects and cost-effectiveness of orlistat in obese type 2 diabetic patients. Diabetes Care 2002 Feb; 25 (2): 303-8
41. Maetzel A, Ruof J, Covington M, et al. Economic evaluation of orlistat in overweight and obese patients with type 2 diabetes mellitus. Pharmacoeconomics 2003; 21 (7): 501-12
42. Finer N, James WP, Kopelman PG, et al. One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes Relat Metab Disord 2000 Mar; 24 (3): 306-13
43. Hill JO, Hauptman J, Anderson JW. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-year study. Am J Clin Nutr 1999; 69: 1108-16
44. McDuffie JR, Calis KA, Uwaifo GI, et al. Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res 2002 Jul; 10 (7): 642-50
45. Zhi J, Moore R, Kanitra L. The effect of short-term (21-day) orlistat treatment on the physiologic balance of six selected macrominerals and microminerals in obese adolescents. J Am Coll Nutr 2003 Oct; 22 (5): 357-62
46. McDuffie JR, Calis KA, Booth SL, et al. Effects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy 2002 Jul; 22: 814-22